Articles 2013

Abstract
Digitalis-like immunoreactive substances (DLISs) have been shown to cross-react with anti-digoxin antibodies. We previously reported that eplerenone, the structure of which is similar to that of digoxin,interfered with digoxin measurements in a fluorescence polarization immunoassay (FPIA), microparticle enzyme immunoassay (MEIA), and affinity column-mediated immunoassay (ACMIA),and also that the extent of interference was different in each assay. Digoxin has a narrow therapeutic window; therefore, it is important to measure its serum concentrations without interference by clinically co-administered drugs. In this study, we performed two additional types of assays (enzyme multiplied immunoassay technique (EMIT) and chemiluminescent immunoassay (CLIA)) to clarify cross-reactivity between eplerenone and anti-digoxin antibodies. Furthermore, we used EMIT and CLIA to measure apparent digoxin concentrations in mixed solutions of eplerenone (1-100 μg/mL) and digoxin (1-3 ng/mL). Eplerenone was not detected as digoxin by EMIT and CLIA in cross-reaction tests. Furthermore, the apparent concentration of digoxin when co-administered with eplerenone was not significantly affected in EMIT and CLIA. These results suggest that EMIT and CLIA may be able to accurately measure serum digoxin concentrations in patients adjunctively receiving eplerenone.
Key words: DLIS, eplerenone, EMIT, CLIA, therapeutic drug monitoring

Abstract
The biomedical laboratory science profession and the professionals who work in this field are dedicated to deliver the best possible services to patients because it is essential in the promotion of quality health care. The information generated with the completion of human genome project has and continues to transform human clinical medicine by pinpointing at the molecular level the causes of diseases that heretofore were unknown. In addition, the impact of the human genome project has created the emerging science of biological therapy, meaning future medicines will be tailored
made for every patient each with their own specific diagnosis based upon their own individual genetic blueprint. Thus, as discoveries are made at the bench then tested at the bedside to eventually enter delivery to communities, the revolution of translational medicine is upon us. How will the biomedical laboratory respond to these changes both in terms of the profession as a whole but importantly how each and every laboratory professional addresses these changes that are revolutionizing the practice of the laboratory profession and laboratories in general? To best address these changes will require all laboratory professionals to have a quality sense of ethics, especially as it relates to making good, sound decisions. This quality will be paramount to determining how these changes will be implemented such that the delivery of quality health care to our patients will not be compromised. This paper addresses many of the concerns involved in making sound ethical decisions.
Key words: biomedical laboratory science, ethics, good decision making

Abstract
Acanthamoeba is a suitable model to study eukaryotic cells as regards disinfectants, survival and growth. It could be a general model for such studies and can represent several eukaryotic human parasites. In the present study a new disinfectant product BioCoolR was tested for ability to kill Acanthamoeba castellani a free-living amoebae present in the environment. By count of the viable cells 2% of final concentration of BioCoolRsubstance inhibits viability of A castellani.after 1, 2 and 24 hour according to the p value of t-test which was 0.002, 0.049 and 0.001 respectively.
Key words: water, amoeba, parasits

CONTENTS

Minireview

Original Articles

Published 【PDF】